Replies to post #11030 on Health Discovery Corp (HDVY)

[imperativity]

Here you go! I still follow this stock even though I liquidated long ago. Here is to hoping this is true! Would be one heck of a vindication for this technology.

Hi Bill,
Just listened to CC. NEO is aiming for an early 2016 launch of Flow. Doug commented it will change the way Flow Cytromety is performed around the world.
Can we expect sub-licensing ?
Thx Bill,
SMG

Bill's response:

Hello,
That was a very welcome statement by Van Oort and reflects what we’ve been told is NEO’s great enthusiasm for – and it’s important to note this – SVM-based Flow. HDC does not have the right to sublicense but frankly, that’s irrelevant. If we bring a potential flow customer to NEO, they handle everything and we still get a 50% royalty rate.


You may be aware that the worldwide market for flow cytometry is about $6 billion. NEO uses it in cancer; I don’t know how much of the total market cancer accounts for but as NEO has a very small share, there’s potentially a major opportunity if ours is indeed a material advance over competing techniques. I believe the Premier and Clarient deals will – in time – expand Flow's revenue potential far beyond what anyone could reasonably have envisioned earlier this year. (And that includes NeoLAB and cyto too). BTW, after NEO revenue reaches a cumulative $20 million benchmark on any and all HDC-based products (NeoLAB, flow and cyto) for which HDC will get $5 million, royalty rates of 6.5% on NeoLAB and 50% on flow and cyto then kick in.


Incidentally, Van Ort also targeted 1Q as the launch for NeoLAB, so if both of these happen then, we should start to see some cash flow in 2Q. For reference and perspective, the excerpts below on flow cytometry are from Wikipedia. Hope this helps. CC transcript attached.


Bill